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Abstract: 
Background  
Follow-up studies of weight gain related to antipsychotic treatment beyond 
a year are limited in number. We compared weight change in the three 
most commonly prescribed antipsychotics in a representative UK General 
Practice database.  
Method  
We conducted a cohort study in United Kingdom primary care records of 
people newly prescribed olanzapine, quetiapine or risperidone. The primary 
outcome was weight in each six month period for two years after treatment 
initiation. Weight changes were compared using linear regression, adjusted 
for age, baseline weight and diagnosis.  
Results  
6338 people received olanzapine, 12984 quetiapine and 6556 risperidone. 
Baseline weight was lowest for men treated with olanzapine (80.8 Kg 
versus 83.5Kg quetiapine, 82.0 Kg risperidone) and women treated with 
olanzapine (67.7Kg versus 71.5Kg quetiapine 68.4Kg risperidone. Weight 
gain occurred during treatment with all three drugs. Compared to 
risperidone mean weight gain was higher with olanzapine (adjusted co-
efficient +1.24kg (95% CI: 0.69kg-1.79kg per 6 months) for men and 
+0.77kg (95% CI: 0.29kg-1.24kg) for women).  Weight gain with 
quetiapine was lower in unadjusted models compared to risperidone, but 





Olanzapine is more commonly prescribed to people with lower weight. 
However, after accounting for baseline weight, age, sex and diagnosis, 
olanzapine is still associated with greater weight gain over two years than 
risperidone or quetiapine. Baseline weight does not ameliorate the risks of 
weight gain associated with antipsychotic medication. Weight gain should 
be assertively discussed and managed for people prescribed antipsychotics, 
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Follow-up studies of weight gain related to antipsychotic treatment beyond a year are limited in 
number. We compared weight change in the three most commonly prescribed antipsychotics in a 
representative UK General Practice database. 
Method 
We conducted a cohort study in United Kingdom primary care records of people newly prescribed 
olanzapine, quetiapine or risperidone. The primary outcome was weight in each six month period for 
two years after treatment initiation. Weight changes were compared using linear regression, adjusted 
for age, baseline weight and diagnosis.  
Results 
6338 people received olanzapine, 12984 quetiapine and 6556 risperidone. Baseline weight was lowest 
for men treated with olanzapine (80.8 Kg versus 83.5Kg quetiapine, 82.0 Kg risperidone) and women 
treated with olanzapine (67.7Kg versus 71.5Kg quetiapine 68.4Kg risperidone. Weight gain occured 
during treatment with all three drugs. Compared to risperidone mean weight gain was higher with 
olanzapine (adjusted co-efficient +1.24kg (95% CI: 0.69kg-1.79kg per 6 months) for men and +0.77kg 
(95% CI: 0.29kg-1.24kg) for women).  Weight gain with quetiapine was lower in unadjusted models 
compared to risperidone, but this difference was not significant after adjustment.  
Conclusion 
Olanzapine is more commonly prescribed to people with lower weight. However, after accounting for 
baseline weight, age, sex and diagnosis, olanzapine is still associated with greater weight gain over two 
years than risperidone or quetiapine. Baseline weight does not ameliorate the risks of weight gain 


































































associated with antipsychotic medication. Weight gain should be assertively discussed and managed for 
people prescribed antipsychotics, especially olanzapine. 
 
  



































































Weight gain is a common adverse effect of antipsychotic medications, especially in the short term 
(weeks to months of treatment).  People with severe mental illnesses (SMI; such schizophrenia, other 
non-affective psychotic illnesses and bipolar disorder) who receive these drugs are already at increased 
risk of obesity, diabetes and cardiovascular disease (de Hert et al.. 2009, Osborn et al. 2007, Osborn et 
al. 2008). These elevated cardiovascular risks are also reported across broader diagnostic groups such as 
depression (
 
Daskalopoulou et al. 2016) and even in people experiencing psychotic symptoms but no 
SMI diagnosis (Moreno et al., 2013). Antipsychotic agents are currently the first line treatments for 
control of psychotic symptoms, as well as for relapse prevention. The mixture of adverse effects and 
therapeutic benefit makes it difficult for the patients and their clinicians to choose the most appropriate 
drug and dose (Leucht et al., 2013). 
 The extent of antipsychotic related weight gain in clinical practice over multiple years of treatment is 
not well understood. There is some trial evidence that antipsychotic related weight gain is more 
pronounced in the early weeks of treatment, and that people who are underweight or of normal weight 
are more likely to develop significant weight gain (defined as greater than 7% of body weight)
 
(Cooper et 
al., 2016). Younger people may also be more prone to significant antipsychotic related weight gain
 
(Manu et al., 2015). There is less evidence regarding longer term effects. A recent meta-analysis of 
randomized controlled trials suggested weight gain extended up to 48 weeks after commencing 
antipsychotics, although few of the studies in the analysis had follow-up periods approaching 48 weeks 
in duration (Bak et al., 2014). Observational cohorts have found variation in weight change with a range 
of antipsychotics, but olanzapine (a D2 and 5-HT2 receptor antagonist)  is commonly associated with 
greatest weight gain (Musil et al., 2015). In order that clinicians and patients can make a choice of using 
an appropriate antipsychotic drug, we need to know the risk of gaining weight in real life clinical 


































































settings.  This will inform preventative strategies against weight gain and associated mortality.  Routine 
clinical data offer an opportunity to describe weight gain in representative clinical samples.  
Aims 
We aimed to describe recorded weight changes in people receiving their first prescriptions for the three 
most commonly prescribed antipsychotic medications in the UK namely risperidone (a D2, 5-HT2 and NE 
alpha-2 receptor antagonist), olanzapine and quetiapine (a D2 and 5-HT2 receptor antagonist and NET 
reuptake inhibitor)
 
(Marston et al., 2014)  
Methods 
Study design 
This was a retrospective cohort study of primary care data recorded between January 1, 2006 and 
December 31, 2014. We aimed to compare weight in patients receiving one of three antipsychotics as 
monotherapy and to assess weight change over two years.  We included all eligible participants in the 
follow up to mirror an intention to treat analysis in a trial. 
Setting 
We used data from The Health Improvement Network (THIN), a large primary care database comprising 
of electronic medical records from more than 12 million patients across the UK (The Health 
Improvement Network 2016). General practices that contribute patient data to the THIN network 
provide anonymised clinical data from patient consultations and administration, generating longitudinal 
records. Demographic and clinical variables are available the latter are entered as hierarchical Read 
codes (Chisholm 1990) Townsend score is available as a measure of local social deprivation. Patient 
populations registered in THIN are representative of the UK population as a whole (Dave and Petersen 


































































2009), with prescription and consultation rates that are similar to other sources of national statistics. 
The quality of the records from each practice is assured by comparing the mortality rates recorded by 
the practice to national mortality statistics.
 
We only included practices that had an acceptable mortality 
rate (AMR) recording, as well as acceptable computer usage (ACU) levels, throughout the whole study 
period (Maguire et al., 2009). Finally, we only included practices where at least 80% of patients had a 
value for Townsend Score. 
Participants  
We included patients within THIN with a new prescription of the three most widely prescribed 
antipsychotics in the UK: olanzapine, quetiapine or risperidone. If a patient was prescribed one or more 
of these medications;  only their first prescription period was considered (for example, if they had an 
initial first prescription of olanzapine followed by  their first prescription of quetiapine, only their period 
of time prescribed olanzapine prescription would be included in the study). Patients previously exposed 
to any antipsychotic medication were excluded from the cohort. Patients may have been prescribed 
other medications during the study period. We included patients aged between 18 and 99 (inclusive) on 
the date of their first incident antipsychotic prescription. Patients without a record for sex, age or 
Townsend Score were excluded, and we only included patients with a minimum of two years of follow 
up before and after their first prescription of olanzapine, quetiapine or risperidone.  
Study Variables 
The main outcome of interest was recorded weight over a two year period, compared to their “baseline 
weight”. Baseline weight was defined as the value of the latest weight recording in the two-year period 
before their incident antipsychotic prescription. Anyone without a weight recording during this two-year 
period was excluded. Any weight recordings in the two-year period after each patient’s incident 
antipsychotic prescription were extracted with the date of that recording. We also extracted data 


































































regarding the patients’ age, sex, Townsend score (scored 1- 5, with increasing value for increasing 
deprivation level of an area equivalent to 150 households), and record of SMI history.  SMI was defined 
as ever having a record of any of the following: bipolar disorders, schizophrenia like conditions, other 
psychoses, or being on a practice based SMI register. These were defined according to published Read 
code lists from previous work (Marston et al., 2014; Osborn et al., 2015).  
Analysis 
For each of the three drugs, we identified patients who had at least one recording of their weight in the 
two year period before their incident antipsychotic prescription.  For patients with a weight recording 
after their initial antipsychotic prescription, we calculated the mean of these weight recordings during 
six-month periods after their incident prescription, namely at 0-6, 6-12, 12-18 and 18-24 months.  
We derived stepwise linear regression models with weight difference per 6 months as the outcome 
variable. We adjusted for age, SMI diagnosis, social deprivation, baseline weight and timing of weight 
recording (days since incident antipsychotic prescription). The unadjusted model was initially tested 
with the inclusion of an interaction term for sex, to determine whether subsequent models should be 
run separately for each sex. All models included a random effect by patient, in order to account for the 
lack of independence between weight recordings within the same person. Effect estimates were 
reported with 95% confidence intervals and p-values at the α = 0.05 cut-off value. We performed an 
additional analysis excluding people over the age of 65, who may have different baseline risks for weight 
change and different indications for antipsychotic treatment. In addition, we calculated the rate of 
greater than 7% of baseline weight gain at two years from antipsychotic initiation. 
The project received approval from the THIN Scientific Review committee at IMS Health in April 2016.  
SRC Reference Number: 16THIN013 
 



































































We identified 8117, 15653 and 7887 patients with a first prescription of olanzapine, quetiapine and 
risperidone prescription during the study period.  Of these, 6338 (78.1%), 12984 (82.9%) and 6556 
(83.1%), respectively, had a weight recording in the two-year period prior to their incident antipsychotic 
prescription, and were eligible for inclusion in our analysis in terms of having a ‘baseline’ weight. Of 
those with missing baseline weight 45.9% were men and 54.1% were women, the mean age was 50.9 
years (standard deviation 20.5) and 44.4% had an SMI diagnosis. . Table 1 shows the demographics of 
the included patients, according to the antipsychotic drug they were prescribed and sex. Baseline weight 
was lower before prescribing olanzapine, in both men and women (table 1) Over the two year follow-up, 
the proportions receiving at least one weight record were 5168/6556 (78.8%) for risperidone, 5777 
(91.15%) for olanzapine and 10378 (79.9%) for quetiapine. 
In the first stage of linear regression, we ran the unadjusted model with and without an additional drug-
sex interaction term. The likelihood ratio test between these two models found the interaction to be 
highly significant (p < 0.001), and so all subsequent statistical analysis was stratified by sex. 
The mean weight recordings within each of the subsequent six-month periods after first prescription are 
shown in Figure 1, again by antipsychotic drug and sex.  
Weight gain coefficients from the linear regression models are shown in table 2. Townsend score did not 
significantly improve the performance of either of the fully-adjusted models and was not included in the 
final models. All models indicated that patients prescribed olanzapine were significantly more likely to 
put on more weight than patients taking risperidone, with fully-adjusted estimated difference of +1.24kg 
(95% CI: 0.69kg to 1.79kg) per six months for men and +0.77kg (95% CI: 0.29kg to 1.24kg) per six months 
for women. The unadjusted models suggested a significant difference in weight change between 
quetiapine and risperidone users for both men and women but these effects were no longer significant 


































































in the adjusted models. In the reduced cohort of individuals under the age of 65, results were similar. In 
the fully adjusted model, compared to risperidone weight gain in the olanzapine treated group was 
+0.94kg (95% CI 0.50kg to 1.38kg) per six months, weight change in the quetiapine treated group was -
0.11kg (-0.51kg to 0.29kg) per six months. 
By two years, the rate of greater than 7% weight gain in men was 22.01 (95% CI 20.07-24.14) per 100 
person-years (pys) for those treated with risperidone, 27.20 (95% CI 25.14-29.43) per 100 pys for those 
treated with olanzapine and 19.14 (95% CI 17.79-20.60) per 100 pys for those prescribed quetiapine. In 
women rates were 24.59 (95% CI 22.86-26.44), 29.54 (95% CI 27.72-31.48) and 24.33 (95% CI 23.18-
25.54) per 100 pys for treatment with risperidone, olanzapine and quetiapine respectively.  
Discussion 
Our results show that people receiving all thr e antipsychotic agents, who have their weight measured, 
show progressive weight gain over a two year period, running contrary to the belief that weight 
stabilizes within the short to medium term (Haddad, 2005) and in line with the only other large 
longitudinal study we are aware of which examines this (Bushe et al., 2012). People prescribed 
olanzapine had a lower average baseline weight than people prescribed risperidone and quetiapine but 
they gained more weight in the first six months of treatment and this pattern is continued up to two 
years after the first prescription.  This increased weight gain was not explained by differences in age or 
sex, and remained true after adjusting for the lower weight of the olanzapine group at baseline, and 
adjusting for whether someone had a history of SMI. In the supplementary analysis; the proportion of 
people gaining more than 7% weight was higher for olanzapine, compared to risperidone.  
The strengths of our study include the large representative sample of thousands of people receiving a 
new prescription of olanzapine risperidone or quetiapine in the UK. The natural design demonstrates 


































































the true extent of recorded weight gain associated with these agents in real life clinical practice, and 
mimics an intention to treat analysis. 
The limitations include missing data; not every patient has measurements of weight at each of the time 
points in real life clinical practice, and there was a slight (2-3%) increased chance for people  in the  
olanzapine group to have a weight record during the later stages of follow-up, compared to the other 
two agents. Similar numbers of people had weight recordings in the first six months of follow-up for 
each drug so the results cannot be fully explained by recording or surveillance bias. However while the 
figures allow valid comparisons between the agents, we cannot claim that the mean weight gain reflects 
the true absolute weight gain seen in those who do not have weight recordings. We deliberately kept 
our analysis simple to describe real life effects. Our analyses are presented using the entire cohorts 
prescribed olanzapine, risperidone and quetiapine and not stratified by diagnostic group. However we 
did adjust for diagnosis in the multivariate analysis and weight gain with olanzapine remained 
significantly higher. The lack of difference in weight gain in the quetiapine treated group, compared to 
risperidone, might reflect the use of lower doses for non-SMI indications. Future studies might assess 
the role of antipsychotic dose or duration of treatment, ideally over even longer time periods. They 
could also explore subgroups who move between different categories of obesity including those who 
lose significant amounts of weight. However missing data at different time points make this type of 
analysis challenging in observational data . Indeed, the lower weight gain in the quetiapine treated 
group might reflect lower doses for non-SMI indications. 
Our findings highlight the importance of discussing weight gain with people prescribed any of these 
three antipsychotic medications, and exploring the risks and benefits of each agent, especially 
olanzapine. In particular, in order to make informed decisions about their treatment, individuals should 
be aware of the potential for continued weight gain over at least two years in real life practice. We 


































































cannot be certain of the potential for weight gain beyond two years but it is potentially sustained. This 
discussion should include lifestyle advice and should adhere to the latest guidelines regarding weight 
gain. Guidelines are available regarding weight gain with antipsychotics and This suggestincludes 
considering agents such as metformin when weight gain would be a particular concern, or using 
aripiprazole as an alternative or additional treatment to olanzapine
 
(Cooper et al., 2016). Our results 
also highlight the importance of monitoring weight during treatment with antipsychotics as well as other 
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Figure 1: Mean weight recordings (kg) for each of the four six-month periods after patients’ incident 
antipsychotic prescription (olanzapine: red, quetiapine: blue, risperidone: green  
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Table 1: Demographics of patients with a baseline weight recording, by antipsychotic drug and sex. Age and baseline weight reported as mean (SD), 
Townsend score and psychiatric diagnosis as frequency (%). 
 Olanzapine Quetiapine Risperidone 
  Men (n = 2789) Women (n = 3549) Men (n = 5025) Women (n = 7959) Men (n = 2819) Women (n = 3737) 
Age (years) 48.6 (17.8) 53.4 (19.3) 57.1 (20.3) 55.5 (21.6) 56.9 (21.3) 62.5 (21.9) 
Baseline weight (kg) 80.8 (18.0) 67.7 (18.0) 83.5 (19.0) 71.5 (20.1) 82.0 (19.0) 68.4 (19.0) 
Townsend score 
      
1 379 (13.6%) 638 (18.0%) 903 (18.0%) 1368 (17.2%) 465 (16.5%) 704 (18.8%) 
2 438 (15.7%) 667 (18.8%) 851 (16.9%) 1345 (16.9%) 476 (16.9%) 641 (17.2%) 
3 538 (19.3%) 697 (19.6%) 1018 (20.3%) 1762 (22.1%) 598 (21.2%) 786 (21.0%) 
4 690 (24.7%) 824 (23.2%) 1139 (22.7%) 1895 (23.8%) 598 (21.2%) 849 (22.7%) 
5 744 (26.7%) 723 (20.4%) 1114 (22.2%) 1589 (20.0%) 682 (24.2%) 757 (20.3%) 
Diagnosis 
      
SMI 1044 (37.03) 1230 (32.91) 1277 (45.79)  1544 (43.51) 1489 (29.63) 2464 (30.96) 
Schizophrenia 486 (17.24) 419 (11.21) 445 (15.96) 391 (11.02) 492 (9.79) 509 (6.40) 
Bipolar disorder 158 (5.60) 263 (7.04) 341 (12.23) 574 (16.17) 510 (10.15) 1119 (14.06) 
Other SMI 356 (12.63) 454 (15.31) 427 (15.31) 508 (14.31) 366 (7.28) 581 (7.30) 
SMI register 44 (1.56) 94 (2.52) 64 (2.29) 71 (2.00) 121 (2.41) 255 (3.20) 
Non-SMI 1367 (48.49) 2145 (57.40) 1178 (42.24) 1733 (48.83) 2884 (57.39) 4897 (61.53) 
































































Anxiety 446 (15.82) 645 (17.26) 571 (20.47) 746 (21.02) 1056 (21.01) 1803 (22.65) 
Depression 321 (11.39) 567 (15.17) 497 (17.82) 772 (21.75) 860 (17.11) 1714 (21.54) 
Dementia 600 (21.28) 933 (24.97) 110 (3.94) 215 (6.06) 968 (19.26) 1380 (17.34) 
No code 408 (14.47) 362 (9.69) 334 (11.98) 272 (7.66) 652 (12.98) 598 (7.51) 
 




































































        
   Change in weight per 6 month period (kg) compared to risperidone 
 
  Unadjusted  Age adjusted Age + SMI adjusted 
Age + SMI +  
baseline weight + half-year 
adjusted 
 
risperidone 0 [baseline] 0 [baseline] 0 [baseline] 0 [baseline] 
Men 
olanzapine 
2.05 (95% CI 1.47 to 2.63, 
p<0.001) 
1.52 (95% CI 0.95 to 2.08), 
p<0.001) 
1.51 (95% CI 0.94 to 2.07), 
p<0.001) 




-0.51 (95% CI -1.03 to 0.01, 
p=0.052) 
-0.40 (95% CI -0.91 to 0.10, 
p=0.115) 
-0.38 (95% CI -0.88 to  0.12, 
p=0.138) 
-0.29 (95% CI -0.79 to 0.20, 
p=0.240) 
 
risperidone 0 [baseline] 0 [baseline] 0 [baseline] 0 [baseline] 
Women 
olanzapine 
1.90 (95% CI 1.41 to 2.39, 
p<0.001) 
1.17 (95% CI 0.69 to  1.65), 
p<0.001) 
1.16 (95% CI 0.69 to 1.64, 
p<0.001) 




0.65 (95% CI 0.23 to  1.07), 
p=0.002) 
0.06 (95% CI: -0.35 to 0.47), 
p=0.781) 
0.07 (95% CI -0.33 to 0.48), 
p=0.726) 
0.20 (95% CI -0.20 to 0.60, 
p=0.323) 
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